Keryx Biopharmaceuticals Announces Changes to its Board of Directors
September 13 2017 - 4:10PM
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical
company focused on bringing innovative medicines to people with
kidney disease, today announced the appointment of Mark J. Enyedy
as an independent member of the company’s board of directors. Mr.
Enyedy brings extensive biopharmaceutical leadership experience to
the company. John Butler, chairman of the Keryx board of directors
and president and chief executive officer of Akebia Therapeutics,
Inc., has resigned from Keryx’s board. Current Keryx board member
Michael Rogers has been appointed as chairman of the board. These
changes are effective immediately.
“On behalf of the entire board, we look forward to Mike’s
chairmanship and thank John for his contributions to our company,”
said Greg Madison, president, chief executive officer and board
member of Keryx Biopharmaceuticals. “We are thrilled to have Mark
join our board. His experience building leading biopharmaceutical
organizations will be invaluable to Keryx as we work to pursue our
vision of building a leading multi-product company focused on
kidney disease.”
“Keryx has a unique opportunity, as it prepares for the
potential launch of an additional indication for Auryxia, to help
more than one million adults with chronic kidney disease in the
United States manage two complications of this illness,” said Mr.
Enyedy. “Auryxia has all of the characteristics of a foundational
medicine from which Keryx can build a leading multi-product company
focused on improving outcomes for people with kidney disease. I
look forward to working with the Keryx team in realizing this
vision.”
“It has been a pleasure to work with the Keryx team,” said Mr.
Butler. “I am proud of our accomplishments during my time on the
board and I look forward to following the company's continued
success.”
Mr. Enyedy has more than 25 years of combined general
management, business development, and legal experience in the
biotechnology industry across multiple therapeutic areas. He
currently serves as president and chief executive officer of
ImmunoGen, Inc., a position he has held since 2016. Prior to
ImmunoGen, Mr. Enyedy served as executive vice president and head
of corporate development for Shire plc leading the company's
strategy, merger and acquisitions, and corporate planning functions
and providing commercial oversight for the company's pre-Phase 3
portfolio. Previously, Mr. Enyedy served as chief executive officer
of Proteostasis Therapeutics, Inc., following 15 years at Genzyme
Corporation in diverse roles, and president of the transplant,
oncology, and multiple sclerosis divisions. Before joining Genzyme,
Mr. Enyedy was an associate with the law firm Palmer & Dodge.
He holds a J.D. from Harvard Law School and a B.S. from
Northeastern University. Mr. Enyedy also serves on the board of
directors of Fate Therapeutics.
Pursuant to the company’s October 2015 financing transaction
with The Baupost Group, LLC., Mr. Enyedy replaces Mr. Butler as
Baupost’s board appointee.
About Keryx Biopharmaceuticals, Inc.Keryx
Biopharmaceuticals, Inc., with headquarters in Boston,
Massachusetts, is focused on the development and commercialization
of innovative medicines that provide unique and meaningful
advantages to people with kidney disease. The Keryx team consists
of approximately 200 committed people working with passion to
advance the care of people with this complex disease. In September
2014, the U.S. Food and Drug Administration approved Keryx’s first
medicine, Auryxia® (ferric citrate) tablets. For more information
about Keryx, please visit www.keryx.com.
Forward Looking Statements Some of the
statements included in this press release, particularly those
regarding the commercialization and ongoing clinical development of
Auryxia and the submission of an sNDA to the FDA to
expand the label of ferric citrate to include the treatment of IDA
in adults with stage 3-5 NDD-CKD and the potential approval in this
indication and the impact thereof on Keryx, may be forward-looking
statements that involve a number of risks and uncertainties. For
those statements, we claim the protection of the safe harbor for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. Among the factors that could cause
our actual results to differ materially are the following: whether
we can increase adoption of Auryxia in patients with CKD on
dialysis in order to achieve our 2017 financial guidance; whether
we can maintain our operating expenses to projected levels while
continuing our current clinical, regulatory and commercial
activities; the risk that the FDA may not concur with our
interpretation of our Phase 3 study results in NDD- CKD, supportive
data, conduct of the studies, or any other part of our regulatory
submission and could ultimately deny approval of ferric citrate for
the treatment of IDA in adults with stage 3-5 NDD-CKD; the risk
that if approved for use in NDD-CKD that we may not be able to
successfully market Auryxia for use in this indication; our ability
to continue to supply Auryxia to the market; and other risk factors
identified from time to time in our reports filed with
the Securities and Exchange Commission. Any forward looking
statements set forth in this press release speak only as of the
date of this press release. We do not undertake to update any of
these forward looking statements to reflect events or circumstances
that occur after the date hereof. This press release and prior
releases are available at http://www.keryx.com. The
information found on our website is not incorporated by reference
into this press release and is included for reference purposes
only.
KERYX BIOPHARMACEUTICALS CONTACTS:Amy
SullivanSenior Vice President, Corporate AffairsT: 617.466.3519
amy.sullivan@keryx.com
Lora PikeSenior Director, Investor Relations & Corporate
CommunicationsT: 617.466.3511lora.pike@keryx.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Sep 2023 to Sep 2024